Acasti Pharma Inc reports results for the quarter ended in December - Earnings Summary

Grace Therapeutics

12/02/2024 14:31

* Acasti Pharma Inc  ACST.OQ  reported a quarterly adjusted
loss
of 30 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -54 cents.  The lone analyst forecast for the
quarter was for a loss of 31 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Acasti Pharma Inc's reported EPS for the quarter was a
loss
of 29 cents​.
    * The company reported a quarterly loss of C$3.26 million.
    * Acasti Pharma Inc shares had fallen by 15.2% this quarter.

FORECAST CHANGES
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Acasti Pharma Inc
is $6.00 
This summary was machine generated from LSEG data February 12 at
02:31 p.m. UTC. ​All figures in Canadian dollars unless
otherwise stated. (For questions concerning the data in this
report, contact Estimates.Support@lseg.com. For any other
questions or feedback, contact
RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.31          -0.30          Beat
                                  -0.27          
                                  -0.46          
 Mar. 31 2023      -0.84          -3.90          Missed